Clinical Trials
60 trialsEvaluation for NCI Surgery Branch Clinical Research Protocols
National Institutes of Health Clinical Center (CC)
Natural History Study of Early Life Exposures in Agriculture (ELEA)
National Institutes of Health Clinical Center (CC)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
DP-04
AstraZeneca
SURVIMON
N.N. Petrov National Medical Research Center of Oncology
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
LONGEVITI
University of Alberta
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response
University Health Network, Toronto
iCaRe2
University of Nebraska
ELEPHAS-02
Elephas
CER
Cancer Support Community, Research and Training Institute, Philadelphia
TraveraRTGx
Travera Inc
NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts
The Christie NHS Foundation Trust
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Ohio State University
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
University of Oklahoma
SCORE
Natera, Inc.
ELEPHAS-05
Elephas
LIBERATE
University Health Network, Toronto
NEUTROFLOW
OncoHost Ltd.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma
Indiana University
SBRT
Mayo Clinic
ORACLE
Guardant Health, Inc.
Serpentine
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics
Mayo Clinic
Eligibility Screening for the NIH Intramural Research Program Clinical Protocols
National Institutes of Health Clinical Center (CC)
PREFER
Labcorp Corporation of America Holdings, Inc
EVIDENT
Sheffield Teaching Hospitals NHS Foundation Trust
MOHCCN-O
University Health Network, Toronto
ROOT
Taproot Health
SkinHealth
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
National Institutes of Health Clinical Center (CC)
REGATA
N.N. Petrov National Medical Research Center of Oncology
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
POSITive
European Institute of Oncology
Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease
Vanderbilt University Medical Center
Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma
University of Nebraska
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Fate Therapeutics
Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study
Namida Lab
Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease
National Institutes of Health Clinical Center (CC)
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
IMEPOCA
Nantes University Hospital
PARADIGM
VastBiome
ADOPT
University of Dundee
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
TScan Therapeutics, Inc.
HSP70CTC
Charite University, Berlin, Germany
PIONEER
SpeciCare
ICI-DISCOVER
Università Politecnica delle Marche
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Prometheus Laboratories